Last reviewed · How we verify
gemtuzumab ozogamycin
Gemtuzumab ozogamicin is a monoclonal antibody targeting CD33 on acute myeloid leukemia cells, delivering a cytotoxic calicheamicin payload directly to leukemic blasts.
Gemtuzumab ozogamicin is a monoclonal antibody targeting CD33 on acute myeloid leukemia cells, delivering a cytotoxic calicheamicin payload directly to leukemic blasts. Used for Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory.
At a glance
| Generic name | gemtuzumab ozogamycin |
|---|---|
| Also known as | gemtuzumab ozogamycin (MYLOTARG ®) |
| Sponsor | Nantes University Hospital |
| Drug class | Monoclonal antibody-drug conjugate (ADC) |
| Target | CD33 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug binds to CD33, a myeloid antigen expressed on AML blasts, and undergoes internalization. Once inside the cell, the calicheamicin payload is released and causes DNA double-strand breaks, leading to apoptosis. This antibody-drug conjugate approach allows targeted delivery of cytotoxic chemotherapy to leukemic cells while sparing normal tissues.
Approved indications
- Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Hepatotoxicity (elevated transaminases)
- Veno-occlusive disease (VOD)
- Infection
- Nausea and vomiting
- Infusion reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |